These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
144 related articles for article (PubMed ID: 35051577)
1. Discovery of orexin 2 receptor selective and dual orexin receptor agonists based on the tetralin structure: Switching of receptor selectivity by chirality on the tetralin ring. Iio K; Saitoh T; Ohshita R; Hino T; Amezawa M; Takayama Y; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H Bioorg Med Chem Lett; 2022 Mar; 60():128555. PubMed ID: 35051577 [TBL] [Abstract][Full Text] [Related]
2. Design and synthesis of novel orexin 2 receptor agonists based on naphthalene skeleton. Hino T; Saitoh T; Nagumo Y; Yamamoto N; Kutsumura N; Irukayama-Tomobe Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H Bioorg Med Chem Lett; 2022 Mar; 59():128530. PubMed ID: 35007725 [TBL] [Abstract][Full Text] [Related]
3. Design and Synthesis of Orexin 1 Receptor-Selective Agonists. Iio K; Hashimoto K; Nagumo Y; Amezawa M; Hasegawa T; Yamamoto N; Kutsumura N; Takeuchi K; Ishikawa Y; Yamamoto H; Tokuda A; Sato T; Uchida Y; Inoue A; Tanimura R; Yanagisawa M; Nagase H; Saitoh T J Med Chem; 2023 Apr; 66(8):5453-5464. PubMed ID: 37043436 [TBL] [Abstract][Full Text] [Related]
4. Design and synthesis of novel orexin 2 receptor agonists with a 1,3,5‑trioxazatriquinane skeleton. Amezawa M; Yamamoto N; Nagumo Y; Kutsumura N; Ishikawa Y; Yanagisawa M; Nagase H; Saitoh T Bioorg Med Chem Lett; 2023 Feb; 82():129151. PubMed ID: 36690040 [TBL] [Abstract][Full Text] [Related]
5. Discovery of Arylsulfonamides as Dual Orexin Receptor Agonists. Zhang D; Perrey DA; Decker AM; Langston TL; Mavanji V; Harris DL; Kotz CM; Zhang Y J Med Chem; 2021 Jun; 64(12):8806-8825. PubMed ID: 34101446 [TBL] [Abstract][Full Text] [Related]
6. TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice. Yukitake H; Fujimoto T; Ishikawa T; Suzuki A; Shimizu Y; Rikimaru K; Ito M; Suzuki M; Kimura H Pharmacol Biochem Behav; 2019 Dec; 187():172794. PubMed ID: 31654653 [TBL] [Abstract][Full Text] [Related]
7. TAK-994, a Novel Orally Available Brain-Penetrant Orexin 2 Receptor-Selective Agonist, Suppresses Fragmentation of Wakefulness and Cataplexy-Like Episodes in Mouse Models of Narcolepsy. Ishikawa T; Hara H; Kawano A; Tohyama K; Kajita Y; Miyanohana Y; Koike T; Kimura H J Pharmacol Exp Ther; 2023 Jun; 385(3):193-204. PubMed ID: 37001988 [TBL] [Abstract][Full Text] [Related]
8. Design and Synthesis of Non-Peptide, Selective Orexin Receptor 2 Agonists. Nagahara T; Saitoh T; Kutsumura N; Irukayama-Tomobe Y; Ogawa Y; Kuroda D; Gouda H; Kumagai H; Fujii H; Yanagisawa M; Nagase H J Med Chem; 2015 Oct; 58(20):7931-7. PubMed ID: 26267383 [TBL] [Abstract][Full Text] [Related]
9. Orexin in sleep, addiction and more: is the perfect insomnia drug at hand? Hoyer D; Jacobson LH Neuropeptides; 2013 Dec; 47(6):477-88. PubMed ID: 24215799 [TBL] [Abstract][Full Text] [Related]
10. Structure-based development of a subtype-selective orexin 1 receptor antagonist. Hellmann J; Drabek M; Yin J; Gunera J; Pröll T; Kraus F; Langmead CJ; Hübner H; Weikert D; Kolb P; Rosenbaum DM; Gmeiner P Proc Natl Acad Sci U S A; 2020 Jul; 117(30):18059-18067. PubMed ID: 32669442 [TBL] [Abstract][Full Text] [Related]
11. Blockade of orexin-1 receptors attenuates orexin-2 receptor antagonism-induced sleep promotion in the rat. Dugovic C; Shelton JE; Aluisio LE; Fraser IC; Jiang X; Sutton SW; Bonaventure P; Yun S; Li X; Lord B; Dvorak CA; Carruthers NI; Lovenberg TW J Pharmacol Exp Ther; 2009 Jul; 330(1):142-51. PubMed ID: 19363060 [TBL] [Abstract][Full Text] [Related]
12. The orexin receptor 2 (OX2R)-selective agonist TAK-994 increases wakefulness without affecting cerebrospinal fluid orexin levels in cynomolgus monkeys. Yamada R; Narita N; Ishikawa T; Kakehi M; Kimura H Pharmacol Biochem Behav; 2024 Jan; 234():173690. PubMed ID: 38061670 [TBL] [Abstract][Full Text] [Related]
13. Discovery of highly potent and selective orexin 1 receptor antagonists (1-SORAs) suitable for in vivo interrogation of orexin 1 receptor pharmacology. Stump CA; Cooke AJ; Bruno J; Cabalu TD; Gotter AL; Harell CM; Kuduk SD; McDonald TP; O'Brien J; Renger JJ; Williams PD; Winrow CJ; Coleman PJ Bioorg Med Chem Lett; 2016 Dec; 26(23):5809-5814. PubMed ID: 27818110 [TBL] [Abstract][Full Text] [Related]
14. Orexin-1 receptor blockade dysregulates REM sleep in the presence of orexin-2 receptor antagonism. Dugovic C; Shelton JE; Yun S; Bonaventure P; Shireman BT; Lovenberg TW Front Neurosci; 2014; 8():28. PubMed ID: 24592208 [TBL] [Abstract][Full Text] [Related]
15. Essential structure of orexin 1 receptor antagonist YNT-707, Part IV: The role of D-ring in 4,5-epoxymorphinan on the orexin 1 receptor antagonistic activity. Saitoh T; Seki K; Nakajima R; Yamamoto N; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ogawa Y; Ishikawa Y; Tanimura R; Yanagisawa M; Nagase H Bioorg Med Chem Lett; 2019 Sep; 29(18):2655-2658. PubMed ID: 31375290 [TBL] [Abstract][Full Text] [Related]
16. Design and Synthesis of Potent and Highly Selective Orexin 1 Receptor Antagonists with a Morphinan Skeleton and Their Pharmacologies. Nagase H; Yamamoto N; Yata M; Ohrui S; Okada T; Saitoh T; Kutsumura N; Nagumo Y; Irukayama-Tomobe Y; Ishikawa Y; Ogawa Y; Hirayama S; Kuroda D; Watanabe Y; Gouda H; Yanagisawa M J Med Chem; 2017 Feb; 60(3):1018-1040. PubMed ID: 28051300 [TBL] [Abstract][Full Text] [Related]
17. The present and future of synthetic orexin receptor agonists. Saitoh T; Sakurai T Peptides; 2023 Sep; 167():171051. PubMed ID: 37422012 [TBL] [Abstract][Full Text] [Related]
18. Requirement of intact disulfide bonds in orexin-A-induced stimulation of gastric acid secretion that is mediated by OX1 receptor activation. Okumura T; Takeuchi S; Motomura W; Yamada H; Egashira Si S; Asahi S; Kanatani A; Ihara M; Kohgo Y Biochem Biophys Res Commun; 2001 Feb; 280(4):976-81. PubMed ID: 11162621 [TBL] [Abstract][Full Text] [Related]
19. Both Ox1r and Ox2r orexin receptors contribute to the cardiovascular and locomotor components of the novelty stress response in the rat. Beig MI; Dampney BW; Carrive P Neuropharmacology; 2015 Feb; 89():146-56. PubMed ID: 25239810 [TBL] [Abstract][Full Text] [Related]
20. Expression of orexin receptors 1 (OX1R) and 2 (OX2R) in the porcine pituitary during the oestrous cycle. Kaminski T; Smolinska N; Nitkiewicz A; Przala J Anim Reprod Sci; 2010 Jan; 117(1-2):111-8. PubMed ID: 19394166 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]